Balancing bleeding and clotting risks during surgery

Stopping Antiplatelets Before Surgery: Is It Really Worth the Risk?

Rhea Morgan monogram
Rhea Morgan in Health & Wellness October 2026 • 4 min read.

"New research questions the long-held practice of halting antiplatelet therapy before non-cardiac surgeries, urging patients and doctors to weigh potential bleeding and clotting risks carefully."


If you're scheduled for surgery and take antiplatelet medications like aspirin or clopidogrel, you've probably heard the standard advice: stop taking them a few days beforehand. The reason? These drugs, crucial for preventing blood clots in people with heart conditions, also thin the blood, potentially leading to excessive bleeding during and after surgery.

This practice, aimed at minimizing bleeding risks, has been a cornerstone of surgical planning for years. However, emerging evidence is causing experts to rethink this approach. What if stopping these medications isn't as beneficial as we thought, or worse, what if it actually increases the risk of dangerous blood clots?

A recent comprehensive review has turned conventional wisdom on its head, suggesting that the decision to continue or discontinue antiplatelet therapy before surgery may not significantly impact the risk of bleeding and could even elevate the risk of life-threatening clots. Let's dive into this game-changing research and explore what it means for you.

AI Search Multiple angles on this topic

Balancing Bleeding and Thrombotic Risk

Premature discontinuation of antiplatelet therapy can increase the risk of perioperative acute coronary syndromes, with stent thrombosis described as especially feared because of its high morbidity and mortality. Antiplatelet management should be based on an individual assessment of the patient's risks and the procedure involved. Expert guidance emphasizes risk stratification, but the final decision rests with the treating physician.

The Antiplatelet Paradox: Balancing Bleeding and Clotting Risks

Balancing bleeding and clotting risks during surgery

Antiplatelet drugs are essential for preventing dangerous blood clots in people with a history of heart attack, stroke, or stent placement. They work by inhibiting the ability of platelets to clump together and form clots. While this is life-saving in preventing heart attacks and strokes, it presents a challenge when surgery is needed. The dilemma is simple: how do you balance the risk of bleeding during surgery with the risk of a clot forming if the medication is stopped?

Traditionally, surgeons and doctors have leaned towards stopping antiplatelet medications to reduce the chances of excessive bleeding, a move that made intuitive sense. However, this approach isn't without its own dangers. When antiplatelet drugs are halted, even for a short period, the risk of a thrombotic event like a heart attack or stroke increases, particularly in patients with cardiac stents.

  • Myocardial Infarction and Acute Coronary Syndromes: Recommended for individuals post-heart attack or with unstable angina.
  • Coronary Stents: Crucial to prevent clots from forming within the stent, especially in the initial months after placement.
  • Stroke and Transient Ischemic Attack (TIA): Used to reduce the risk of further strokes by preventing clot formation in the brain's blood vessels.
AI Search Multiple angles on this topic

Current Evidence on Aspirin

A recent review reports that aspirin may be continued perioperatively when bleeding risk is low. For procedures with high bleeding risk, the same review states that aspirin should be stopped 7 days before surgery and restarted within 24 hours after surgery if adequate hemostasis has been achieved. Another review found that planned aspirin discontinuation was not associated with a statistically significant increase in major adverse cardiac events, although outcomes showed a trend toward being worse after discontinuation.

Limits of the Evidence

Evidence comparing continuation and discontinuation of antiplatelet therapy in non-cardiac surgery remains limited. The available studies included few participants and few events, making firm conclusions difficult. The GRADE assessment downgraded all outcomes because of limited evidence, and wide confidence intervals suggested imprecision for mortality and blood loss requiring transfusion.

Comparing Management Strategies

Comparative evidence on antiplatelet management includes a study of patients undergoing non-cardiac surgery after cardiac stenting that compared discontinuing 1,750 patients with continuing one or both antiplatelet agents in 1,832 patients across nine institutions. The most common surgeries requiring discontinuation were reported in the Veterans Affairs evidence review, although the supplied summary does not specify them. A separate 2026 meta-analysis examined anticoagulant therapy versus antiplatelet therapy after coronary endarterectomy, where no guidelines currently address postoperative use of these therapies.

This creates a challenging paradox: acting to prevent one risk (bleeding) may inadvertently increase another (thrombosis). The latest research attempts to untangle this conundrum and provide clearer guidance.

What It Means for You: A New Era of Personalized Medicine

The most important takeaway from this analysis is that there isn't a one-size-fits-all answer. The decision to continue or discontinue antiplatelet therapy before surgery needs to be a highly individualized one, made in close consultation with your doctor and surgeon. Factors to consider include your specific cardiac history, the type of surgery you're undergoing, and your overall risk profile.

AI Search Multiple angles on this topic

An Evidence Gap in Practice

A 2022 systematic review summarized the available evidence on perioperative management of patients receiving long-term antiplatelet therapy who require elective surgery or procedures. It highlighted an urgent need for further research, particularly as more patients take one or more antiplatelet agents. For major oral and maxillofacial surgery, one review states that evidence-based perioperative guidelines are not available, while existing guidance for minor oral surgery is based on consensus and expert opinion.

A Complex Perioperative Problem

Dual antiplatelet therapy reduces cardiovascular death, myocardial infarction, and recurrent adverse ischemic events in patients with acute coronary syndromes. However, its use creates challenges when patients urgently require coronary artery surgery. Reviews of spinal surgery similarly describe the management of antiplatelet therapy as a balance between thromboembolic events and potential perioperative bleeding.

Individualized Decisions After PCI

The optimal perioperative management of antiplatelet therapy remains unclear for patients undergoing non-cardiac surgery within one year of percutaneous coronary intervention. A real-world cohort study sought to identify predictors of antiplatelet cessation in this setting. The central clinical challenge is balancing cardiovascular or thrombotic risk against bleeding risk, with the latter driven by the bleeding risk of the specific surgery or procedure.

Five trials tested continuation versus stopping therapy

  • 666 randomized adultsThe review combined five randomized controlled trials involving 666 adults.[1]

What the randomized evidence actually shows

Across these trials, continuing treatment and stopping it produced broadly similar measured outcomes for mortality, bleeding that required surgery, and ischaemic events, but the certainty of those findings was low.[1]

  • Only two studies had prospective trial registration and low risk of selective reporting bias.[1]

What five randomized trials found before elective non-cardiac surgery

PopulationAdults taking single or dual antiplatelet therapy, scheduled for elective non-cardiac surgery, with at least one cardiac risk factor[1]
Sample size666 randomized adults[1]
SettingElective general surgery under general, spinal, or regional anaesthesia[1]
ComparisonDiscontinuation of antiplatelet therapy for at least five days before surgery[1]
Main outcomeAll-cause mortality at longest follow-up up to six months and all-cause mortality up to 30 days[1]
RegistrationTwo studies had prospective registration with clinical trial registers[1]
Times cited71[1]

How this review fits later perioperative evidence

A later patient-safety review summarized this Cochrane analysis as finding little or no overall difference between continuing and stopping antiplatelet therapy, while reporting fewer ischaemic events with continuation in absolute terms.[2]

What the trials leave unresolved

  • Can these findings reliably distinguish which types of non-cardiac surgery have materially different bleeding consequences?[1]
  • Would a larger set of randomized events narrow the uncertainty around mortality and transfusion outcomes?[1]

Sources

  1. Continuation versus discontinuation of antiplatelet therapy for bleeding and ischaemic events in adults undergoing non-cardiac surgery (Wiley, 2018)
  2. FactFinders for patient safety: Antithrombotics and interventional pain procedures -- lumbar transforaminal epidural steroid injections and lumbar medial branch radiofrequency neurotomy (2021)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

This article is based on research published under:

DOI-LINK: 10.1002/14651858.cd012584.pub2, Alternate LINK

Title: Continuation Versus Discontinuation Of Antiplatelet Therapy For Bleeding And Ischaemic Events In Adults Undergoing Non-Cardiac Surgery

Subject: Pharmacology (medical)

Journal: Cochrane Database of Systematic Reviews

Publisher: Wiley

Authors: Sharon R Lewis, Michael W Pritchard, Oliver J Schofield-Robinson, Phil Alderson, Andrew F Smith

Published: 2018-07-18

Everything You Need To Know

1

What are antiplatelet medications and what do they do?

Antiplatelet medications, like aspirin and clopidogrel, are drugs that prevent blood clots by inhibiting platelets from clumping together. They are crucial for individuals with heart conditions, such as those who have experienced a heart attack, stroke, or have had coronary stents placed. These medications help prevent potentially life-threatening thrombotic events. These events include myocardial infarction and acute coronary syndromes which help to stop further damage. The key function is to keep blood flowing freely, preventing clots from forming and causing further health complications.

2

Why has it been standard practice to stop antiplatelet medications before surgery?

The conventional practice has been to stop antiplatelet medications a few days before surgery to reduce the risk of bleeding during and after the procedure. This approach is based on the understanding that these drugs thin the blood, which can lead to excessive bleeding. However, there is growing evidence challenging this long-held practice, as stopping these medications may not significantly reduce bleeding risks and could increase the risk of dangerous blood clots, especially in patients with cardiac stents. Therefore, this practice is under review due to the potential for increased thrombotic events.

3

What are the risks associated with stopping antiplatelet therapy before surgery?

The primary risk of stopping antiplatelet therapy before surgery is the increased chance of thrombotic events, such as heart attacks or strokes. For patients with conditions like cardiac stents, the risk is particularly high. These medications are vital for preventing blood clots in these patients, and discontinuing them, even temporarily, can lead to clot formation and potentially life-threatening consequences. This is especially concerning given that these medications are often crucial for preventing myocardial infarction and further strokes.

4

How should the decision to continue or discontinue antiplatelet therapy be made?

The decision to continue or discontinue antiplatelet therapy before surgery should be highly individualized, considering your specific cardiac history, the type of surgery, and your overall risk profile. Close consultation with your doctor and surgeon is essential. They will evaluate the balance between the risk of bleeding during surgery and the risk of a thrombotic event if the medication is stopped. This personalized approach is a shift from the previous one-size-fits-all advice, reflecting a move toward more tailored medical care.

5

Why are antiplatelet medications particularly important for individuals with coronary stents?

Coronary stents are small, mesh tubes placed in arteries to keep them open after procedures like angioplasty. Antiplatelet medications are critical after stent placement to prevent blood clots from forming within the stent. If a clot forms in the stent (stent thrombosis), it can lead to a heart attack. Therefore, continuing antiplatelet therapy, or carefully managing its discontinuation, is vital in these cases to minimize the risk of thrombotic events. This helps ensure the stent functions correctly and the patient's blood flow remains unobstructed, especially in the initial months after placement.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.